Current Status and Prospects of Multimodal Treatment for Upper Gastrointestinal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 389
Special Issue Editor
Interests: upper gastrointestinal cancer; esophageal cancer; gastric cancer; esophagogastric junction cancer; chemotherapy; oncology; endoscopic resection; minimally invasive surgery; robotic surgery
Special Issue Information
Dear Colleagues,
In the field of upper gastrointestinal (GI) cancer treatment, surgery and adjuvant therapy remain standard, but the optimal treatment is becoming increasingly complex and technical. For patients with advanced cancer, aggressive multimodal treatment is thought to reduce recurrence rates and improve their prognosis. Therefore, the proper understanding and application of multimodal treatment combining chemotherapy, radiotherapy, immunotherapy, and minimally invasive surgery is essential to obtain better treatment outcomes.
This Special Issue will focus on the latest technologies used in various multimodal treatments for upper GI cancer and which are expected to improve a poor prognosis. We welcome the submission of the latest original research and comprehensive review articles on all therapies that play a role in the treatment of resectable, locally advanced, metastatic, and recurrent upper GI cancer.
Dr. Koichi Okamoto
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- upper gastrointestinal cancer
- esophageal cancer
- gastric cancer
- esophagogastric junction cancer
- chemotherapy
- oncology
- endoscopic resection
- minimally invasive surgery
- robotic surgery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
